Patents Examined by Lei Yao
  • Animal model of longevity and related methods for increasing longevity and inhibiting tumorigenesis
    Patent number: 11254719
    Abstract: A genetically-modified non-human animal model of longevity and increased health span, which is associated with reduced tumorigenesis and tumor metastasis, as well as related methods for increasing longevity and health span, reducing tumorigenesis and tumor metastasis, and identifying active agents that confer increased longevity or health span, or reduced tumorigenesis or tumor metastasis.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: February 22, 2022
    Assignee: Academia Sinica
    Inventors: Che-Kun James Shen, Yu-Chiau Shyu
  • A*03 restricted peptides for use in immunotherapy against cancers and related methods
    Patent number: 11246917
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: February 15, 2022
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Colette Song, Linus Backert, Heiko Schuster, Daniel Johannes Kowalewski, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh
  • Methods and compounds for reducing threonyl-tRNA synthetase activity
    Patent number: 11225653
    Abstract: The invention includes, in part, methods and compounds for treating diseases and conditions characterized by elevated threonyl-tRNA synthetase (TARS) activity, which include, but are not limited to diseases and conditions in which angiogenesis is elevated as compared to normal. In some embodiments of the invention, a level of a TARS molecule is determined and compared to a control level of TARS to assess a treatment for a disease or condition characterized by elevated TARS activity.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: January 18, 2022
    Assignee: University of Vermont and State Agricultural College
    Inventors: Christopher Francklyn, Karen M. Lounsbury, Jason Botten
  • BH3 peptides and methods of use thereof
    Patent number: 11225511
    Abstract: The invention provides peptides and the nucleic acid sequences that encode them. The invention further provides therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: January 18, 2022
    Assignees: Howard Hughes Medical Institute, Dana-Farber Cancer Institute, Inc.
    Inventors: Stanley J. Korsmeyer, Anthony Letai
  • Tumor infiltrating lymphocytes for treatment of cancer
    Patent number: 11219645
    Abstract: Tumor infiltrating lymphocytes (TILs) are white blood cells that are actively recruited to the tumor site to mount an immune response against tumor growth and metastasis. The disclosure provides methods for treating cancer that comprise steps of isolating CD8+ T cells from a sample derived from a subject, expanding the CD8+ T cells in the presence of interleukin-10, and ad ministering the expanded CD8+ T cells to the subject. Methods of treating cancer may be used in combination with inhibitors of the complement signaling pathway.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: January 11, 2022
    Assignee: Duke University
    Inventors: You-Wen He, Yu Wang
  • Compounds specific to coronavirus S protein and uses thereof
    Patent number: 11220536
    Abstract: The present disclosure is directed to antibodies, and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus (SARS-CoV-S) and/or the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies and antibodies that bind to and/or compete for binding to the same linear or conformational epitope(s) on CoV-S. Further disclosed are conjugates of anti-CoV-S antibodies, and binding fragments thereof, conjugated to one or more functional or detectable moieties. Methods of making said anti-CoV-S antibodies and antigen binding fragments thereof are also contemplated.
    Type: Grant
    Filed: August 18, 2021
    Date of Patent: January 11, 2022
    Assignee: Adagio Therapeutics, Inc.
    Inventors: Laura Walker, Laura Deveau, Jonathan Belk, Anna Wec, C. Garrett Rappazzo
  • Anti-TIGIT antibodies and their use as therapeutics and diagnostics
    Patent number: 11214616
    Abstract: Provided are antibodies that specifically bind to TIGIT (T cell immunoreceptor with Ig and ITIM domains, WUCAM or Vstm3) and inhibit Tigit-mediated cellular signaling and activities in immune cells. The anti-TIGIT antibodies can be used to treat or diagnose cancer, infectious diseases or other pathological disorders that may be modulated by Tigit-mediated functions.
    Type: Grant
    Filed: December 29, 2018
    Date of Patent: January 4, 2022
    Assignee: BEIGENE, LTD.
    Inventors: Tong Zhang, Liu Xue, Qi Liu, Min Wei, Kang Li
  • Methods and compositions for identifying leukemic stem cells
    Patent number: 11209435
    Abstract: The present invention provides methods and compositions for identifying leukemic stem cells.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: December 28, 2021
    Assignee: The Charlotte-Mecklenburg Hospital Authority
    Inventor: Jonathan M. Gerber
  • Anti-HLA-G antibodies, compositions comprising anti-HLA-G antibodies and methods of using anti-HLA-G antibodies
    Patent number: 11208487
    Abstract: Provided herein are antibodies that selectively bind to HLA-G and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: December 28, 2021
    Assignee: Tizona Therapeutics
    Inventors: Courtney Beers, John Corbin, Doug Hodges, Achim Moesta, Vanessa Soros, Paul Fredrick Widboom, Joseph Robert Warfield
  • Screening for anti-cancer compounds using netrin-1 activity
    Patent number: 11203641
    Abstract: The subject matter of the present invention relates to an in vitro method for the screening of anti-cancer compounds based on the capacity for these compound to interact with netrin-1 receptor and/or to inhibit the dimerization of the intracellular domain of the netrin-1 receptor expressed in tumor cells. The invention also relates to a method for predicting the presence of metastatic or aggressive cancer, or for determining the efficiency of an anti-cancer treatment based on the measuring of the expression level of netrin-1. The invention further comprises kits and compounds as a medicament for the treatment of cancer such as metastatic breast cancer, related to the overexpression of netrin-1 by the tumor cells.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: December 21, 2021
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), CENTRE LEON BERARD
    Inventors: Patrick Mehlen, Agnes Bernet, Julien Fitamant
  • Methods of treating cancer, infectious disease, and autoimmune disease using CXC chemokines
    Patent number: 11197890
    Abstract: The current invention is related to the prevention and treatment of diseases including cancer, autoimmune disease, and infectious disease using CXC chemokines and the receptors to which they agonize. It has been found that certain chemokines, including CXCL4, CXCL9, CXCL10, and CXCL12 have various effects on toll-like receptors in various cell types and these can be utilized for disease treatment and prevention.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: December 14, 2021
    Assignee: New York Society for the Relief of the Ruptured and Crippled, maintaining the Hospital for Special Surgery
    Inventor: Franck Barrat
  • Immunohistochemical assay for detecting expression of programmed death ligand 1 (PD-L1) in tumor tissue
    Patent number: 11193937
    Abstract: The present disclosure provides processes for describing and quantifying the expression of human programmed death ligand-1 (PD-L1) in tumor tissue sections as detected by immunohistochemical assay using an antibody that specifically binds to PD-L1. The results generated using these processes have a variety of experimental, diagnostic and prognostic applications.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: December 7, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Marisa Dolled-Filhart, Kenneth Emancipator, Frank Lynch, Robert H. Pierce, Dianna Wu
  • Compounds specific to coronavirus S protein and uses thereof
    Patent number: 11192940
    Abstract: The present disclosure is directed to antibodies, and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus (SARS-CoV-S) and/or the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies and antibodies that bind to and/or compete for binding to the same linear or conformational epitope(s) on CoV-S. Further disclosed are conjugates of anti-CoV-S antibodies, and binding fragments thereof, conjugated to one or more functional or detectable moieties. Methods of making said anti-CoV-S antibodies and antigen binding fragments thereof are also contemplated.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: December 7, 2021
    Assignee: Adagio Therapeutics, Inc.
    Inventors: Laura Walker, Laura Deveau, Jonathan Belk, Anna Wec, C. Garrett Rappazzo
  • Fusion proteins targeting tumour associated macrophages for treating cancer
    Patent number: 11186641
    Abstract: The present invention relates to cancer immunotherapy. In particular, provided herein are fusion proteins for targeting tumor associated macrophages with immunostimulatory agents.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: November 30, 2021
    Assignee: OSLO UNIVERSITETSSYKEHUS HF
    Inventor: Anders Tveita
  • Breast and ovarian cancer vaccines
    Patent number: 11185578
    Abstract: The compositions described herein include an epitope of a peptide that may elicit an immune response in a subject following administration. The compositions may comprise nucleic acids. The compositions may comprise peptides. The methods described herein include administering a composition comprising an epitope of a peptide to a subject in need thereof.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: November 30, 2021
    Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: Mary L. Disis, Denise Cecil, Meredith Slota
  • Plectin-1 binding antibodies and uses thereof
    Patent number: 11168145
    Abstract: Aspects of the disclosure provide compositions and methods for treating cancer characterized by surface expression of plectin-1. In some embodiments, the disclosure provides anti-plectin-1 antibodies. In some embodiments, the anti-plectin-1 antibodies are conjugated to a targeted moiety (e.g., a therapeutic moiety or a detectable label).
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: November 9, 2021
    Assignee: ZIELBIO, INC.
    Inventors: Kimberly A. Kelly, Julien Dimastromatteo
  • Heparanase-neutralizing monoclonal antibodies
    Patent number: 11161912
    Abstract: The present invention relates to heparanase-neutralizing monoclonal antibodies (m Abs), pharmaceutical composition comprising same, and use thereof for treating a disease or disorder associated with heparanase activity, including but not limited to cancer, inflammation, diabetes and related complications. The present invention further provides combined therapies comprising the heparanase-neutralizing m Ab and an anti-cancer treatment such as chemotherapy or radiation, for treating a proliferative disease in a subject.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: November 2, 2021
    Assignees: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED, HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Israel Vlodavsky, Marina Weissmann, Neta Ilan, Gil Arvatz
  • Breast and ovarian cancer vaccines
    Patent number: 11160853
    Abstract: The compositions described herein include an epitope of a peptide that may elicit an immune response in a subject following administration. The compositions may comprise nucleic acids. The compositions may comprise peptides. The methods described herein include administering a composition comprising an epitope of a peptide to a subject in need thereof.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: November 2, 2021
    Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATON
    Inventors: Mary L. Disis, Denise Cecil, Meredith Slota
  • Detection of cancer by elevated levels of bcl-2
    Patent number: 11156613
    Abstract: The present invention relates to a method for the diagnosis, prognosis, and monitoring of cancer, such as early or late stage ovarian cancer, in a subject by detecting Bcl-2 in a biological sample from the subject, preferably a urine or blood sample. Bcl-2 may be measured using an agent that detects or binds to Bcl-2 protein or an agent that detects or binds to encoding nucleic acids, such as antibodies specifically reactive with Bcl-2 protein or a portion thereof. The invention further relates to kits for carrying out the methods of the invention. The invention further relates to a device for the rapid detection of Bcl-2 in a bodily fluid and methods for rapidly measuring Bcl-2 in a bodily fluid.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: October 26, 2021
    Assignee: UNIVERSITY OF SOUTH FLORIDA
    Inventor: Patricia A. Kruk
  • K-ras mutations and anti-EGFr antibody therapy
    Patent number: 11155876
    Abstract: The present application relates to K-ras mutations, to polynucleotides encoding mutant K-ras polypeptides, and to methods of identifying K-ras mutations. The present application also relates to methods of diagnosing cancer; and methods and kits for predicting the usefulness of anti-EGFr specific binding agents in the treatment of tumors.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: October 26, 2021
    Assignee: AMGEN INC.
    Inventors: Daniel J Freeman, Todd Juan, Robert Radinsky